AstraZeneca's Strategic U.S. Expansion Amid Price-Cutting Moves
AstraZeneca adjusts its U.S. strategy by proposing drug price cuts and expanding local production in response to pressure from President Trump. The company aims to balance pricing globally while boosting U.S. sales. With strong quarterly growth, AstraZeneca plans significant revenue growth by 2030 despite potential tariff challenges.
AstraZeneca is adapting its U.S. growth strategy, introducing drug price cuts amid pressure from President Trump's administration. The pharmaceutical giant seeks to balance global pricing while bolstering its American market presence.
CEO Pascal Soriot confirmed that all U.S. drugs would soon be locally produced. The company anticipates strong local demand to continue driving revenue growth, with recent quarterly profits exceeding expectations.
AstraZeneca's strategic moves come as the company navigates potential U.S. tariffs and direct sales strategies, aiming for an annual revenue target of $80 billion by 2030. Despite headwinds, its focus remains on expanding in the nation's vast healthcare market.
(With inputs from agencies.)
Advertisement
Google News